Use of adjuvant chemotherapy in XXXX in routine practice.

@entity1 @entity5 @entity1149 @entity900 @entity260 @entity3
BACKGROUND: For many years, surgery has been the standard treatment for @entity1 with early-stage @entity1149 ( @entity1149 ). Recent randomized trials demonstrated that @entity900 -based adjuvant chemotherapy increases overall survival. The aim of this study was to analyze the precise use of adjuvant chemotherapy in @entity1 with resected @entity1149 in routine practice. @entity1 AND METHODS: Between January 2004 and May 2005, we retrospectively analyzed 219 @entity1 with early-stage @entity1149 who had undergone surgery at one major surgical center in Paris, Institut Mutualiste Montsouris. @entity1 characteristics, the type of surgery, and indications for adjuvant chemotherapy were analyzed. RESULTS: Eighty-seven of the 219 @entity1 (40%) in this study had been treated with adjuvant chemotherapy. Different factors were associated with doctors not prescribing this treatment: age, comorbidity, @entity5 , node, @entity3 stage, and @entity260 . More than eight different @entity900 -based regimens were used, highlighting considerable heterogeneity in the use of adjuvant chemotherapy in daily practice. There is an increase of adjuvant chemotherapy during the study period. CONCLUSION: @entity900 -based chemotherapy is the standard treatment for @entity1 with resected stage II and IIIA @entity1149 . However, such therapy is used quite heterogeneously in daily practice and specific regimens, and the percentage of @entity1 receiving adjuvant chemotherapy vary from standard recommendations. A prospective follow-up of daily practice regarding the use of adjuvant chemotherapy is warranted.
